miércoles, 9 de septiembre de 2020

Fact Sheet for Healthcare Providers: Bio-Speedy Direct RT-qPCR SARS-CoV-2 | NLM

Disaster Information Management Research Center | NLM

Disaster Information and Emergency Response

09/02/2020 12:00 AM EDT


Source: U.S. Food and Drug Administration (FDA). Published: 9/2/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Bio-Speedy Direct RT-qPCR SARS-CoV-2. The Bio-Speedy Direct RT-qPCR SARS-CoV-2 is authorized for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)

No hay comentarios: